Smith Alla, Banville Debra, Gruver E James, Lenox Jesslyn, Melvin Patrice, Waltzman Mark
Boston Children's Hospital, Boston, Massachusetts; and
South Shore Hospital, South Weymouth, Massachusetts.
Hosp Pediatr. 2019 Mar;9(3):179-185. doi: 10.1542/hpeds.2018-0197. Epub 2019 Feb 6.
The management of severe pediatric asthma exacerbations is variable. The use of clinical pathways has been shown to decrease time to clinical recovery and length of stay (LOS) for critically ill patients with asthma in freestanding children's hospitals. We sought to determine if implementing a clinical pathway for pediatric patients who are on continuous albuterol in a community hospital would decrease time to clinical recovery and LOS.
A clinical pathway for guiding the initiation, escalation, and weaning of critical asthma therapies was adapted to a community hospital without a PICU. There were 2 years of baseline data collection (from September 2014 to August 2016) and 16 months of intervention data collection. Segmented regression analysis of interrupted time series was used to evaluate the pathway's impact on LOS and time to clinical recovery.
There were 129 patients in the study, including 69 in the baseline group and 60 in the intervention group. After pathway implementation, there was an absolute reduction of 10.2 hours (SD 2.0 hours) in time to clinical recovery ( ≤ .001). There was no significant effect on LOS. There was a significant reduction in the transfer rate (27.5% of patients in the baseline period versus 11.7% of patients in the intervention period; = .025). There was no increase in key adverse events, which included the percentage of patients who required ICU-specific therapies while awaiting transfer (7.3% of patients in the baseline period versus 1.7% of patients in the intervention period; = .215).
The implementation of a clinical pathway for the management of critically ill children with asthma and on continuous albuterol in a community hospital was associated with a significant reduction in time to clinical recovery without an increase in key adverse events.
儿童重度哮喘急性发作的管理方式存在差异。临床路径的应用已被证明可缩短独立儿童医院中重症哮喘患儿的临床恢复时间和住院时长(LOS)。我们旨在确定在社区医院为持续使用沙丁胺醇的儿科患者实施临床路径是否会缩短临床恢复时间和住院时长。
将指导重症哮喘治疗启动、升级和撤药的临床路径应用于一家没有儿科重症监护病房(PICU)的社区医院。收集了2年的基线数据(2014年9月至2016年8月)以及16个月的干预数据。采用中断时间序列的分段回归分析来评估该路径对住院时长和临床恢复时间的影响。
本研究共纳入129例患者,其中基线组69例,干预组60例。路径实施后,临床恢复时间绝对缩短了10.2小时(标准差2.0小时)(P≤.001)。对住院时长无显著影响。转诊率显著降低(基线期患者的27.5%与干预期患者的11.7%;P =.025)。关键不良事件未增加,包括等待转诊期间需要ICU特定治疗的患者百分比(基线期患者的7.3%与干预期患者的1.7%;P =.215)。
在社区医院为持续使用沙丁胺醇的重症哮喘患儿实施临床路径,可显著缩短临床恢复时间,且关键不良事件未增加。